Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice.


Prasugrel and ticagrelor are two novel promising antiplatelet agents inhibiting the platelet activation via the adenosine diphosphate pathway. Both achieve a faster, more intense, and more consistent platelet inhibition than clopidogrel. Both novel antiplatelet agents have demonstrated superiority over clopidogrel in large, randomised controlled trials in… (More)
DOI: 10.15420/icr.2014.9.3.164


  • Presentations referencing similar topics